Recent progress in mitochondria-targeting-based nanotechnology for cancer treatment

Qin, Jingbo; Gong, Ningqiang; Liao, Zhihuan; Zhang, Shouwen; Timashev, P. S.; Huo, Shuaidong; Liang, Xing‐Jie

doi:10.1039/d1nr01068a

Cited by 55 publications

(52 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The peptide should have optimum positive charge and hydrophobicity to penetrate the mitochondrial membrane ( Horton et al, 2008 ). Three types of peptides are widely used in constructing mitochondria-targeting nanosystems, such as mitochondria-targeting signal peptides (MTSs), mitochondria-penetrating peptides (MPPs), and Szeto-Schiller (SS) ( Qin et al, 2021 ).…”

Section: Mitochondria and Mitochondria-targeted Nanocarriersmentioning

confidence: 99%

“…Combined with programmed death-ligand 1 (PD-L1), this nanosystem can improve PDT efficacy and enhance the infiltration of cytotoxic T lymphocytes (CTLs) into tumors, indicating the metastasis of cancer and potent inhibition. Glycolysis inhibition can lead to compensatory activation of their oxidative phosphorylation in cancer cells ( Qin et al, 2021 ). Cutting off the energy supply to realize the simultaneous inhibition of both oxidative phosphorylation and glycolysis is the most direct strategy for cancer treatment.…”

Section: Mitochondria-targeting Nanosystems For Cancer Therapymentioning

confidence: 99%

See 1 more Smart Citation

Mitochondria-Targeted Nanocarriers Promote Highly Efficient Cancer Therapy: A Review

Zeng

Fang

Zhang

et al. 2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Mitochondria are the primary organelles which can produce adenosine triphosphate (ATP). They play vital roles in maintaining normal functions. They also regulated apoptotic pathways of cancer cells. Given that, designing therapeutic agents that precisely target mitochondria is of great importance for cancer treatment. Nanocarriers can combine the mitochondria with other therapeutic modalities in cancer treatment, thus showing great potential to cancer therapy in the past few years. Herein, we summarized lipophilic cation- and peptide-based nanosystems for mitochondria targeting. This review described how mitochondria-targeted nanocarriers promoted highly efficient cancer treatment in photodynamic therapy (PDT), chemotherapy, combined immunotherapy, and sonodynamic therapy (SDT). We further discussed mitochondria-targeted nanocarriers’ major challenges and future prospects in clinical cancer treatment.

show abstract

Section: Mitochondria and Mitochondria-targeted Nanocarriersmentioning

confidence: 99%

Section: Mitochondria-targeting Nanosystems For Cancer Therapymentioning

confidence: 99%

Mitochondria-Targeted Nanocarriers Promote Highly Efficient Cancer Therapy: A Review

Zeng

Fang

Zhang

et al. 2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…After modified with mitochondria-targeting ligands, multifunctional nanoplatforms have been constructed for cancer therapy including chemotherapy, PTT, PDT, chemodynamic therapy (CDT), sonodynamic therapy (SDT), radiodynamic therapy (RDT) and combined immunotherapy, which are summarized ( Figure 1 ) in this review. Although a lot of works on mitochondria-targeted drug delivery have been summarized ( Hou et al, 2018 ; Murphy and Hartley, 2018 ; Zhou et al, 2019 ; Liew et al, 2021 ), the reviews on mitochondria-targeted nanotechnology for cancer treatment are few ( Qin et al, 2021 ), thus our report mainly focus on this view point.…”

Section: Introductionmentioning

confidence: 99%

Mitochondria-Targeted Nanomedicine for Enhanced Efficacy of Cancer Therapy

Gao

Tong

et al. 2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Nanomedicines have been designed and developed to deliver anticancer drugs or exert anticancer therapy more selectively to tumor sites. Recent investigations have gone beyond delivering drugs to tumor tissues or cells, but to intracellular compartments for amplifying therapy efficacy. Mitochondria are attractive targets for cancer treatment due to their important functions for cells and close relationships to tumor occurrence and metastasis. Accordingly, multifunctional nanoplatforms have been constructed for cancer therapy with the modification of a variety of mitochondriotropic ligands, to trigger the mitochondria-mediated apoptosis of tumor cells. On this basis, various cancer therapeutic modalities based on mitochondria-targeted nanomedicines are developed by strategies of damaging mitochondria DNA (mtDNA), increasing reactive oxygen species (ROS), disturbing respiratory chain and redox balance. Herein, in this review, we highlight mitochondria-targeted cancer therapies enabled by nanoplatforms including chemotherapy, photothermal therapy (PTT), photodynamic therapy (PDT), chemodynamic therapy (CDT), sonodynamic therapy (SDT), radiodynamic therapy (RDT) and combined immunotherapy, and discussed the ongoing challenges.

show abstract

“…To the current date, one of the most effective methods to specifically target the mitochondria is the covalent attachment of mitochondrial penetrating molecules to carrier systems [ 13 – 14 ]. Several mitochondriotropic moieties such as dequalinium (DQA), triphenylphosphonium (TPP), and mitochondrial penetrating peptides and proteins have been linked to nanotechnology.…”

Section: Introductionmentioning

confidence: 99%

Post-functionalization of drug-loaded nanoparticles prepared by polymerization-induced self-assembly (PISA) with mitochondria targeting ligands

Noy¹,

Fan²,

Stenzel³

2021

Beilstein J. Org. Chem.

View full text Add to dashboard Cite

Herein, the postfunctionalization of different non-fouling PISA particles, prepared from either poly(oligo ethylene glycol methyl ether methacrylate) (pPEGMA) and the anticancer drug PENAO (4-(N-(S-penicillaminylacetyl)amino)phenylarsenonous acid) or zwitterionic 2-methacryloyloxyethyl phosphorylcholine (MPC) and PENAO were reported. Both PISA particles were reacted with triphenylphosphonium (TPP) as mitochondria targeting units in order to evaluate the changes in cellular uptake or the toxicity of the conjugated arsenic drug. Attachment of TPP onto the PISA particles however was found not to enhance the mitochondrial accumulation, but it did influence overall the biological activity of pMPC-based particles in 2D and 3D cultured sarcoma SW982 cells. When TPP was conjugated to the pMPC PISA particles more cellular uptake as well as better spheroid penetration were observed, while TPP on PEG-based PISA had only little effect. It was hypothesized that TPP on the micelle surface may not be accessible enough to allow mitochondria targeting, but more structural investigations are required to elucidate this.

show abstract

Recent progress in mitochondria-targeting-based nanotechnology for cancer treatment

Abstract: Mitochondria play critical roles in the regulation of the proliferation and apoptosis of cancerous cells. Nanosystems for targeted delivery of cargos to mitochondria for cancer treatment have attracted increasing attention...

Cited by 55 publications

References 95 publications

Mitochondria-Targeted Nanocarriers Promote Highly Efficient Cancer Therapy: A Review

Mitochondria-Targeted Nanocarriers Promote Highly Efficient Cancer Therapy: A Review

Mitochondria-Targeted Nanomedicine for Enhanced Efficacy of Cancer Therapy

Post-functionalization of drug-loaded nanoparticles prepared by polymerization-induced self-assembly (PISA) with mitochondria targeting ligands

Contact Info

Product

Resources

About